 | This articlerelies excessively onreferences toprimary sources. Please improve this article by addingsecondary or tertiary sources. Find sources: "OSI Pharmaceuticals" – news ·newspapers ·books ·scholar ·JSTOR(June 2014) (Learn how and when to remove this message) |
.png) | |
| Company type | Subsidiary |
|---|---|
| Industry | Pharmaceutical[1] |
| Founded | 1983 |
| Headquarters | Melville, New York |
Key people | Colin Goddard, CEO Michael G. Atieh, CFO Robert A. Ingram, Chairman[1] |
| Products | Biopharmaceuticals Biotherapeutics |
| Revenue |  $375.7 MillionUSD (2006)[2] |
| $-582.2 MillionUSD (2006)[2] | |
Number of employees | 554 (2007-02)[3] |
| Parent | Astellas Pharma (2010-present) |
OSI Pharmaceuticals, Inc. was an Americanpharmaceutical company formerly based inLong Island, New York with facilities inColorado,New Jersey and theUnited Kingdom. On Sunday, May 16, 2010 OSI agreed to be acquired byJapan-based,TSE-listedAstellas Pharma for $4.0 billion.[4] The deal was closed on June 9, 2010. The company closed its last facilities in Long Island in May 2013.[5] OSI had specialized in the discovery and development of molecular targeted therapies. Thoughoncology was the top priority for OSI, research and development targetingtype 2 diabetes andobesity had been conducted through their U.K. subsidiaryProsidion Limited.[6][1] OSI had also made a foray into the ophthalmology market through a marketing agreement withPfizer over Macugen (Pegaptanib) forAge-related macular degeneration; however, acquisition of the firmEyetech, meant to provide control over this product and diversify the company, was unsuccessful, ending in divestiture.[7][8]
In mid-2007, OSI's revenues were based primarily on proceeds from Tarceva sales (which are shared withGenentech andHoffmann–La Roche) and royalty payments related todipeptidyl-peptidase IV inhibitor intellectual property.[7]
Tarceva (Erlotinib) was OSI'sflagship and, as of 2007, only marketed product.[7][9] Tarceva is a small moleculeinhibitor of theepidermal growth factor receptor (EGFR) and is the only EGFR inhibitor to have demonstrated the ability to improve overall survival in advanced non-small celllung cancer and advancedpancreatic cancer.[6] Tarceva was discovered byPfizer as CP-358774 (Moyer et al. Cancer Research, 1997, 57:4838), renamed OSI-774 when Pfizer was required to divest the compound in order to complete the buyout of Warner-Lambert/Parke-Davis and subsequently developed by OSI in conjunction withGenentech.
As of February 7, 2007, our number of employees decreased to 554, of which 276 primarily are involved in research, development and manufacturing activities and 140 primarily are involved in the commercialization of our products.
OSI has a single marketed product backed by a mostly early-stage pipeline.
As a result of our decision to divest the eye disease business held by our wholly owned subsidiary, (OSI) Eyetech, Inc., the operating results for (OSI) Eyetech are shown as discontinued operations...
